Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Genotype frequencies of the seven polymorphisms in subgroups of invasive breast cancer.

From: Interleukin gene polymorphisms and breast cancer: a case control study and systematic literature review

Tumour Severity Subgroups Genotype frequencies (%) Chi square test for trend (P value)
   1:1 1:2 2:2  
IL1A +4845 G>T
Tumour Grade Grade 1 (n = 122) 62 (50.8%) 50 (41%) 10 (8.2%) X2 = 0.037; p = 0.85
  Grade 2 (n = 283) 151 (53.4%) 109 (38.5%) 23 (8.1%)  
  Grade 3 (n = 216) 115 (53.2%) 82 (38%) 19 (8.8%)  
Nodal Involvement Absent (n = 430) 204 (47.4%) 118 (43.7%) 38 (8.8%) X2 = 4.75; p = 0.03*
  Present (n = 117) 117 (59.4%) 63 (32%) 17 (8.6%)  
Vascular Invasion Absent (n = 467) 243 (52%) 185 (39.6%) 39 (8.4%) X2 = 0.058; p = 0.81
  Present (n = 117) 64 (54.7%) 42 (35.9%) 11 (9.4%)  
IL1B -511 C>T
Tumour Grade Grade 1 (n = 126) 51 (40.5%) 59 (46.8%) 16 (12.7%) X2 = 0.12; p = 0.73
  Grade 2 (n = 284) 150 (52.8%) 111 (39.1%) 23 (8.1%)  
  Grade 3 (n = 216) 98 (45.4%) 93 (43.1%) 25 (11.6%)  
Nodal Involvement Absent (n = 434) 214 (49.3%) 179 (41.2%) 41 (9.4%) X2 = 0.79; p = 0.37
  Present (n = 198) 90 (45.5%) 87 (43.9%) 21 (10.6%)  
Vascular Invasion Absent (n = 473) 224 (47.4%) 201 (42.5%) 48 (10.1%) X2 = 0.38; p = 0.54
  Present (n = 116) 57 (49.1%) 50 (43.1%) 9 (7.8%)  
IL1B +3954 C>T
Tumour Grade Grade 1 (n = 121) 68 (56.2%) 48 (39.7%) 5 (4.1%) X2 = 0.053; p = 0.82
  Grade 2 (n = 279) 173 (62%) 90 (32.3%) 16 (5.7%)  
  Grade 3 (n = 215) 131 (60.9%) 70 (32.6%) 14 (6.5%)  
Nodal Involvement Absent (n = 427) 244 (57.1%) 161 (37.7%) 22 (5.2%) X2 = 0.37; p = 0.54
  Present (n = 194) 120 (61.9%) 61 (31.4%) 13 (6.7%)  
Vascular Invasion Absent (n = 464) 283 (61%) 157 (33.8%) 24 (5.2%) X2 = 0.43; p = 0.51
  Present (n = 114) 66 (57.9%) 41 (36%) 7 (6.1%)  
IL1RN +2018 T>C
Tumour Grade Grade 1 (n = 125) 55 (44%) 55 (44%) 15 (12%) X2 = 0.73; p = 0.40
  Grade 2 (n = 280) 150 (53.6%) 107 (38.2%) 23 (8.2%)  
  Grade 3 (n = 215) 108 (50.2%) 86 (40%) 21 (9.8%)  
Nodal Involvement Absent (n = 429) 216 (50.3%) 180 (42%) 33 (7.7%) X2 = 0.11; p = 0.74
  Present (n = 196) 102 (52%) 72 (36.7%) 22 (11.2%)  
Vascular Invasion Absent (n = 463) 232 (50.1%) 191 (41.3%) 40 (8.6%) X2 = 1.34; p = 0.25
  Present (n = 118) 67 (56.8%) 42 (35.6%) 9 (7.6%)  
IL4R +1902 A>G
Tumour Grade Grade 1 (n = 137) 87 (63.5%) 44 (32.1%) 6 (4.4%) X2 = 0.14; p = 0.71
  Grade 2 (n = 308) 195 (63.3%) 97 (31.5%) 16 (5.2%)  
  Grade 3 (n = 228) 146 (64%) 75 (32.9%) 7 (3.1%)  
Nodal Involvement Absent (n = 477) 313 (65.6%) 144 (30.2%) 20 (4.2%) X2 = 0.11; p = 0.75
  Present (n = 212) 135 (63.7%) 69 (32.5%) 8 (3.8%)  
Vascular Invasion Absent (n = 508) 316 (62.2%) 170 (33.5%) 22 (4.3%) X2 = 0.002; p = 0.96
  Present (n = 129) 82 (63.6%) 40 (31%) 7 (5.4%)  
IL6 -174 G>C
Tumour Grade Grade 1 (n = 80) 26 (32.5%) 38 (47.5%) 16 (20%) X2 = 0.04; p = 0.84
  Grade 2 (n = 204) 78 (38.2%) 95 (46.6%) 31 (15.2%)  
  Grade 3 (n = 159) 49 (30.8%) 83 (52.2%) 27 (17%)  
Nodal Involvement Absent (n = 293) 100 (34.1%) 141 (48.1%) 52 (17.7%) X2 = 0.20; p = 0.66
  Present (n = 143) 52 (36.4%) 67 (46.9%) 24 (16.8%)  
Vascular Invasion Absent (n = 325) 112 (34.5%) 159 (48.9%) 54 (16.6%) X2 = 0.001; p = 0.98
  Present (n = 85) 29 (34.1%) 42 (49.4%) 14 (16.5%)  
IL10 -1082 G>A
Tumour Grade Grade 1 (n = 80) 23 (28.8%) 37 (46.3%) 20 (25%) X2 = 0.37; p = 0.54
  Grade 2 (n = 205) 39 (19%) 113 (55.1%) 53 (25.9%)  
  Grade 3 (n = 158) 44 (27.8%) 79 (50%) 35 (22.2%)  
Nodal Involvement Absent (n = 293) 69 (23.5%) 148 (50.5%) 76 (25.9%) X2 = 0.84; p = 0.36
  Present (n = 143) 38 (26.6%) 73 (51%) 32 (22.4%)  
Vascular Invasion Absent (n = 325) 87 (26.8%) 156 (48%) 82 (25.2%) X2 = 3.3; p = 0.07
  Present (n = 85) 12 (14.1%) 49 (57.6%) 24 (28.2%)